Bedaquiline: a review of human pharmacokinetics and drug-drug interactions

Bedaquiline has recently been approved for the treatment of pulmonary multidrug-resistant tuberculosis (TB) as part of combination therapy in adults. It is metabolized primarily by the cytochrome P450 isoenzyme 3A4 (CYP3A4) to a less-active N-monodesmethyl metabolite. Phase I and Phase II studies in...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of antimicrobial chemotherapy Ročník 69; číslo 9; s. 2310
Hlavní autoři: van Heeswijk, R P G, Dannemann, B, Hoetelmans, R M W
Médium: Journal Article
Jazyk:angličtina
Vydáno: England 01.09.2014
Témata:
Antifungal Agents - pharmacology
Antitubercular Agents - pharmacokinetics
Antitubercular Agents - pharmacology
Antiviral Agents - pharmacology
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Diarylquinolines - pharmacokinetics
Diarylquinolines - pharmacology
Drug Interactions
Humans
Tuberculosis, Multidrug-Resistant - drug therapy
CYP3A
clinical trials
HIV
tuberculosis
ISSN:1460-2091, 1460-2091
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Bedaquiline has recently been approved for the treatment of pulmonary multidrug-resistant tuberculosis (TB) as part of combination therapy in adults. It is metabolized primarily by the cytochrome P450 isoenzyme 3A4 (CYP3A4) to a less-active N-monodesmethyl metabolite. Phase I and Phase II studies in healthy subjects and patients with drug-susceptible or multidrug-resistant TB have assessed the pharmacokinetics and drug-drug interaction profile of bedaquiline. Potential interactions have been assessed between bedaquiline and first- and second-line anti-TB drugs (rifampicin, rifapentine, isoniazid, pyrazinamide, ethambutol, kanamycin, ofloxacin and cycloserine), commonly used antiretroviral agents (lopinavir/ritonavir, nevirapine and efavirenz) and a potent CYP3A inhibitor (ketoconazole). This review summarizes the pharmacokinetic profile of bedaquiline as well as the results of the drug-drug interaction studies.
AbstractList Bedaquiline has recently been approved for the treatment of pulmonary multidrug-resistant tuberculosis (TB) as part of combination therapy in adults. It is metabolized primarily by the cytochrome P450 isoenzyme 3A4 (CYP3A4) to a less-active N-monodesmethyl metabolite. Phase I and Phase II studies in healthy subjects and patients with drug-susceptible or multidrug-resistant TB have assessed the pharmacokinetics and drug-drug interaction profile of bedaquiline. Potential interactions have been assessed between bedaquiline and first- and second-line anti-TB drugs (rifampicin, rifapentine, isoniazid, pyrazinamide, ethambutol, kanamycin, ofloxacin and cycloserine), commonly used antiretroviral agents (lopinavir/ritonavir, nevirapine and efavirenz) and a potent CYP3A inhibitor (ketoconazole). This review summarizes the pharmacokinetic profile of bedaquiline as well as the results of the drug-drug interaction studies.Bedaquiline has recently been approved for the treatment of pulmonary multidrug-resistant tuberculosis (TB) as part of combination therapy in adults. It is metabolized primarily by the cytochrome P450 isoenzyme 3A4 (CYP3A4) to a less-active N-monodesmethyl metabolite. Phase I and Phase II studies in healthy subjects and patients with drug-susceptible or multidrug-resistant TB have assessed the pharmacokinetics and drug-drug interaction profile of bedaquiline. Potential interactions have been assessed between bedaquiline and first- and second-line anti-TB drugs (rifampicin, rifapentine, isoniazid, pyrazinamide, ethambutol, kanamycin, ofloxacin and cycloserine), commonly used antiretroviral agents (lopinavir/ritonavir, nevirapine and efavirenz) and a potent CYP3A inhibitor (ketoconazole). This review summarizes the pharmacokinetic profile of bedaquiline as well as the results of the drug-drug interaction studies.
Bedaquiline has recently been approved for the treatment of pulmonary multidrug-resistant tuberculosis (TB) as part of combination therapy in adults. It is metabolized primarily by the cytochrome P450 isoenzyme 3A4 (CYP3A4) to a less-active N-monodesmethyl metabolite. Phase I and Phase II studies in healthy subjects and patients with drug-susceptible or multidrug-resistant TB have assessed the pharmacokinetics and drug-drug interaction profile of bedaquiline. Potential interactions have been assessed between bedaquiline and first- and second-line anti-TB drugs (rifampicin, rifapentine, isoniazid, pyrazinamide, ethambutol, kanamycin, ofloxacin and cycloserine), commonly used antiretroviral agents (lopinavir/ritonavir, nevirapine and efavirenz) and a potent CYP3A inhibitor (ketoconazole). This review summarizes the pharmacokinetic profile of bedaquiline as well as the results of the drug-drug interaction studies.
Author Dannemann, B
Hoetelmans, R M W
van Heeswijk, R P G
Author_xml – sequence: 1
  givenname: R P G
  surname: van Heeswijk
  fullname: van Heeswijk, R P G
  email: rvheesw1@its.jnj.com
  organization: Janssen Infectious Diseases BVBA, Beerse, Belgium rvheesw1@its.jnj.com
– sequence: 2
  givenname: B
  surname: Dannemann
  fullname: Dannemann, B
  organization: Janssen Research & Development, LLC, Titusville, NJ, USA
– sequence: 3
  givenname: R M W
  surname: Hoetelmans
  fullname: Hoetelmans, R M W
  organization: Janssen Infectious Diseases BVBA, Beerse, Belgium
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24860154$$D View this record in MEDLINE/PubMed
BookMark eNpNT0tPwzAYi9AQe8CFH4By5FKWNE3ScIOJpyZxgXOVJV9ZtjbdkgbEv6eIIXGxLdmy7Cka-c4DQueUXFGi2HyjzdxuE5X0CE1oIUiWE0VH__QYTWPcEEIEF-UJGudFKQjlxQQ934LV--Qa5-Eaaxzgw8En7mq8Tq32eLfWodWm2w5-70zE2ltsQ3rPfgA730PQpnedj6fouNZNhLMDz9Db_d3r4jFbvjw8LW6WmWGc9hknss5hpQQoJgy3SoGittaKFSVIqeQwDWRpaysEYaokJYOSalEIxq00LJ-hy9_eXej2CWJftS4aaBrtoUuxolzwQilJ1RC9OETTqgVb7YJrdfiq_v7n3zSXXZE
CitedBy_id crossref_primary_10_1007_s40262_024_01363_6
crossref_primary_10_1007_s00228_024_03749_8
crossref_primary_10_1016_j_ebiom_2018_01_005
crossref_primary_10_1056_NEJMoa2212537
crossref_primary_10_3390_antibiotics10121515
crossref_primary_10_1055_a_1934_8303
crossref_primary_10_1134_S1068162023603257
crossref_primary_10_1093_jpids_piac047
crossref_primary_10_1007_s40262_023_01217_7
crossref_primary_10_1016_j_bmcl_2020_127172
crossref_primary_10_1080_14656566_2017_1309023
crossref_primary_10_1016_j_ejps_2018_08_038
crossref_primary_10_3390_molecules22061001
crossref_primary_10_1128_AAC_00855_17
crossref_primary_10_1016_j_jchromb_2019_02_022
crossref_primary_10_1093_jac_dkaa328
crossref_primary_10_1039_D2BM01835G
crossref_primary_10_1097_FTD_0000000000001164
crossref_primary_10_1183_13993003_02502_2019
crossref_primary_10_1016_j_tube_2023_102318
crossref_primary_10_1016_j_biopha_2018_04_176
crossref_primary_10_1093_cid_ciw165
crossref_primary_10_1016_j_ijtb_2023_04_011
crossref_primary_10_1093_jac_dkac067
crossref_primary_10_4155_bio_14_318
crossref_primary_10_1097_JNC_0000000000000242
crossref_primary_10_3389_fmed_2023_1304857
crossref_primary_10_1128_AAC_01043_21
crossref_primary_10_1371_journal_pmed_1004453
crossref_primary_10_1016_j_jgar_2021_02_017
crossref_primary_10_1002_med_21602
crossref_primary_10_3390_medicina58020188
crossref_primary_10_1128_AAC_00024_21
crossref_primary_10_1007_s11030_021_10335_y
crossref_primary_10_1016_j_jmsacl_2024_01_001
crossref_primary_10_1016_j_molstruc_2023_135359
crossref_primary_10_1093_cid_ciab992
crossref_primary_10_1016_j_ijid_2017_10_019
crossref_primary_10_1038_s41598_023_36955_y
crossref_primary_10_1080_14740338_2019_1648429
crossref_primary_10_1016_j_medmal_2018_11_013
crossref_primary_10_1056_NEJMoa2312928
crossref_primary_10_1002_cmdc_201600441
crossref_primary_10_1016_j_resinv_2019_01_001
crossref_primary_10_1128_aac_01464_24
crossref_primary_10_1016_j_mmifmc_2022_03_001
crossref_primary_10_1111_cts_13718
crossref_primary_10_1371_journal_pmed_1002842
crossref_primary_10_1111_bcp_15380
crossref_primary_10_1016_j_ijtb_2016_08_003
crossref_primary_10_1016_j_ijantimicag_2023_106939
crossref_primary_10_1016_j_jmsacl_2023_12_001
crossref_primary_10_1208_s12248_015_9829_2
crossref_primary_10_1093_emph_eoaf014
crossref_primary_10_3389_fphar_2023_1022090
crossref_primary_10_1136_bmjopen_2020_047185
crossref_primary_10_1080_14656566_2017_1373090
crossref_primary_10_3390_antibiotics12010017
crossref_primary_10_1080_07391102_2023_2259486
crossref_primary_10_1128_aac_00613_24
crossref_primary_10_1111_bcp_15925
crossref_primary_10_1111_bph_15688
crossref_primary_10_1093_jac_dkae103
crossref_primary_10_3390_metabo14010063
crossref_primary_10_1183_13993003_00118_2019
crossref_primary_10_1080_17512433_2016_1200462
crossref_primary_10_1093_cid_ciaa526
crossref_primary_10_1002_jcph_1887
crossref_primary_10_1128_aac_00029_25
crossref_primary_10_1016_S1473_3099_21_00470_9
crossref_primary_10_1080_14740338_2020_1694901
crossref_primary_10_1080_14756366_2021_1919889
crossref_primary_10_1080_17425255_2021_1836158
crossref_primary_10_1177_1740774516665090
crossref_primary_10_1183_13993003_00146_2017
crossref_primary_10_1016_j_bmc_2019_115213
crossref_primary_10_1016_j_ccm_2019_08_001
crossref_primary_10_1128_aac_01275_23
crossref_primary_10_3390_pathogens7010024
crossref_primary_10_1186_s43556_024_00243_6
crossref_primary_10_1073_pnas_2315069121
crossref_primary_10_1080_17512433_2024_2317954
crossref_primary_10_1080_02648725_2022_2076031
crossref_primary_10_1016_j_ijid_2018_09_009
crossref_primary_10_1080_17425255_2016_1183643
crossref_primary_10_1038_ja_2017_126
crossref_primary_10_1093_jac_dkae057
crossref_primary_10_1097_QAI_0000000000003268
crossref_primary_10_1016_j_cell_2023_09_016
crossref_primary_10_1080_01635581_2023_2180825
crossref_primary_10_1007_s11904_023_00678_6
crossref_primary_10_1128_AAC_03246_14
crossref_primary_10_1016_j_mayocp_2018_12_011
crossref_primary_10_1126_science_aat9689
crossref_primary_10_1002_psp4_12768
crossref_primary_10_1126_science_aay0211
crossref_primary_10_1093_cid_ciac252
crossref_primary_10_1111_bcp_13696
crossref_primary_10_2174_0929867325666181120100025
crossref_primary_10_1183_13993003_02510_2020
crossref_primary_10_1093_infdis_jiae332
crossref_primary_10_1128_Spectrum_00434_21
crossref_primary_10_1016_j_ijtb_2023_05_005
crossref_primary_10_1039_D4MD00829D
crossref_primary_10_1007_s00044_024_03295_z
crossref_primary_10_1128_AAC_02404_19
crossref_primary_10_3389_fcimb_2023_1183597
crossref_primary_10_3389_fphar_2023_1154780
crossref_primary_10_1002_cpt_2685
crossref_primary_10_1002_cpt_3536
crossref_primary_10_1186_s12981_016_0118_7
crossref_primary_10_1073_pnas_2426827122
crossref_primary_10_1093_jac_dkv447
crossref_primary_10_1016_j_biopha_2025_118537
crossref_primary_10_1016_S2352_3018_19_30035_9
crossref_primary_10_3390_ph14050461
crossref_primary_10_1016_j_cmi_2020_06_004
crossref_primary_10_1007_s40262_021_00997_0
crossref_primary_10_1128_AAC_02399_20
crossref_primary_10_3390_pathogens12121385
crossref_primary_10_1016_j_ijid_2021_07_038
crossref_primary_10_1007_s15010_025_02620_x
crossref_primary_10_1183_13993003_01908_2019
crossref_primary_10_1016_j_molstruc_2021_130493
crossref_primary_10_1093_cid_ciy727
crossref_primary_10_1093_jac_dku504
crossref_primary_10_3390_idr13020045
crossref_primary_10_1002_psp4_12147
crossref_primary_10_1128_aac_02033_21
crossref_primary_10_1177_0192623317723085
crossref_primary_10_1007_s00228_024_03788_1
crossref_primary_10_1128_AAC_00276_15
crossref_primary_10_1016_j_bmcl_2017_05_081
crossref_primary_10_1007_s40506_018_0145_0
crossref_primary_10_1007_s40121_021_00396_9
crossref_primary_10_1007_s13318_019_00604_5
crossref_primary_10_1093_jac_dkae266
crossref_primary_10_1016_j_trsl_2020_03_007
crossref_primary_10_1002_cpdd_639
crossref_primary_10_1016_j_ejmech_2021_114059
crossref_primary_10_1002_bcp_70163
crossref_primary_10_1016_j_jddst_2023_105253
crossref_primary_10_1016_S2213_2600_17_30079_6
crossref_primary_10_1002_cpdd_1517
crossref_primary_10_1177_20420986211041277
crossref_primary_10_1016_j_ijantimicag_2016_10_020
crossref_primary_10_1002_cpdd_1515
crossref_primary_10_1007_s40262_022_01107_4
crossref_primary_10_7759_cureus_28519
crossref_primary_10_1093_infdis_jiac024
crossref_primary_10_1128_AAC_02179_20
crossref_primary_10_1016_S1473_3099_25_00151_3
crossref_primary_10_3390_jpm12040569
crossref_primary_10_2174_0929867329666220823111812
crossref_primary_10_3390_microorganisms13040722
crossref_primary_10_1128_AAC_00509_16
crossref_primary_10_1007_s00228_025_03871_1
ContentType Journal Article
Copyright The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
Copyright_xml – notice: The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1093/jac/dku171
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1460-2091
ExternalDocumentID 24860154
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GroupedDBID ---
-E4
.2P
.GJ
.I3
.XZ
.ZR
0R~
18M
1TH
29J
2WC
3O-
4.4
482
48X
53G
5GY
5RE
5VS
5WA
5WD
70D
AABZA
AACZT
AAJKP
AAJQQ
AAMVS
AAOGV
AAPGJ
AAPNW
AAPQZ
AAPXW
AARHZ
AAUAY
AAUQX
AAVAP
AAWDT
AAWTL
ABDFA
ABEJV
ABEUO
ABGNP
ABIXL
ABJNI
ABKDP
ABLJU
ABNGD
ABNHQ
ABNKS
ABPQP
ABPTD
ABQLI
ABQNK
ABQTQ
ABSMQ
ABVGC
ABWST
ABXVV
ABZBJ
ACCCW
ACFRR
ACGFO
ACGFS
ACIWK
ACPQN
ACPRK
ACUFI
ACUKT
ACUTJ
ACUTO
ACVCV
ACYHN
ACZBC
ADBBV
ADEYI
ADEZT
ADGZP
ADHKW
ADHZD
ADIPN
ADMTO
ADNBA
ADOCK
ADQBN
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEHUL
AEJOX
AEKPW
AEKSI
AEMDU
AEMQT
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFNX
AFFQV
AFFZL
AFIYH
AFOFC
AFRAH
AFSHK
AFXAL
AFYAG
AGINJ
AGKEF
AGKRT
AGMDO
AGQXC
AGSYK
AGUTN
AHMBA
AHMMS
AHXPO
AI.
AIAGR
AIJHB
AJDVS
AJEEA
AJNCP
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
APIBT
APJGH
APWMN
AQDSO
AQKUS
ASPBG
ATGXG
ATTQO
AVNTJ
AVWKF
AXUDD
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BTRTY
BVRKM
BZKNY
C45
CAG
CDBKE
CGR
COF
CS3
CUY
CVF
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBS
ECGQY
ECM
EE~
EIF
EIHJH
EJD
EMOBN
ENERS
F5P
F9B
FECEO
FEDTE
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HH5
HVGLF
HW0
HZ~
IOX
J21
J5H
JXSIZ
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
M-Z
M49
MBLQV
MHKGH
ML0
N9A
NGC
NOMLY
NOYVH
NPM
NTWIH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OBFPC
OBS
OCZFY
ODMLO
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
O~Y
P2P
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
QBD
R44
RD5
RNI
ROL
ROX
ROZ
RUSNO
RW1
RXO
RZF
RZO
TCURE
TEORI
TJX
TMA
TR2
VH1
W8F
WOQ
X7H
Y6R
YAYTL
YKOAZ
YXANX
ZGI
ZKX
ZXP
~91
~A~
7X8
AJBYB
ID FETCH-LOGICAL-c351t-507f2eb96e936c5d99e91dfa9348e7797860e78dfd660398083e81a64635d7c32
IEDL.DBID 7X8
ISICitedReferencesCount 183
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000343322200002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1460-2091
IngestDate Sat Sep 27 19:06:00 EDT 2025
Thu Apr 03 07:02:23 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords CYP3A
clinical trials
HIV
tuberculosis
Language English
License The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c351t-507f2eb96e936c5d99e91dfa9348e7797860e78dfd660398083e81a64635d7c32
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
OpenAccessLink https://academic.oup.com/jac/article-pdf/69/9/2310/9529209/dku171.pdf
PMID 24860154
PQID 1565499719
PQPubID 23479
ParticipantIDs proquest_miscellaneous_1565499719
pubmed_primary_24860154
PublicationCentury 2000
PublicationDate 2014-09-01
PublicationDateYYYYMMDD 2014-09-01
PublicationDate_xml – month: 09
  year: 2014
  text: 2014-09-01
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Journal of antimicrobial chemotherapy
PublicationTitleAlternate J Antimicrob Chemother
PublicationYear 2014
SSID ssj0006568
Score 2.5318594
SecondaryResourceType review_article
Snippet Bedaquiline has recently been approved for the treatment of pulmonary multidrug-resistant tuberculosis (TB) as part of combination therapy in adults. It is...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 2310
SubjectTerms Antifungal Agents - pharmacology
Antitubercular Agents - pharmacokinetics
Antitubercular Agents - pharmacology
Antiviral Agents - pharmacology
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Diarylquinolines - pharmacokinetics
Diarylquinolines - pharmacology
Drug Interactions
Humans
Tuberculosis, Multidrug-Resistant - drug therapy
Title Bedaquiline: a review of human pharmacokinetics and drug-drug interactions
URI https://www.ncbi.nlm.nih.gov/pubmed/24860154
https://www.proquest.com/docview/1565499719
Volume 69
WOSCitedRecordID wos000343322200002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7UinjxUV_1xQrSU0Oz2WQ360VULCK25FClt7KvSC0kbdMI_ffuJik5CYKXveRBmEwm3-zMfB8At1IGgRebtIRqoh2fCO2wkDOHC8QVdaUSRYPsxxsdDMLRiEXVhltWtVWuY2IRqFUq7R551-QZNpWhiN3P5o5VjbLV1UpCYxM0sIEytqWLjmq2cFKNwvnENd7A0JqelOHuF5ddNc0RRb9Dy-IX09v_78MdgL0KXMKH0hsOwYZOmmCnX5XPm6AdlUTVqw4c1nNXWQe2YVRTWK-OwOujVnyeTywGvYMclgMuMI1hoekHZ9XZU3Pc3gHyREG1yD8du0DLQbEoJyayY_Deex4-vTiV6oIjcYCWjgGIsacFI5phIgPFmGZIxZxhP9SUmqyTuJqGKlaEuMbmBsPpEHHiG-iiqMTeCdhK0kSfARgLxVyFSYB9bAIyEUxhD2FBAsE5V6gFbtbmHBuvtqUKnug0z8a1QVvgtHwn41lJvzH2rG6WQX7nf7j6AuwahOOXTWGXoBGbb1pfgW35vZxki-vCXcw6iPo_XxzLkg
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Bedaquiline%3A+a+review+of+human+pharmacokinetics+and+drug-drug+interactions&rft.jtitle=Journal+of+antimicrobial+chemotherapy&rft.au=van+Heeswijk%2C+R+P+G&rft.au=Dannemann%2C+B&rft.au=Hoetelmans%2C+R+M+W&rft.date=2014-09-01&rft.eissn=1460-2091&rft.volume=69&rft.issue=9&rft.spage=2310&rft_id=info:doi/10.1093%2Fjac%2Fdku171&rft_id=info%3Apmid%2F24860154&rft_id=info%3Apmid%2F24860154&rft.externalDocID=24860154
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1460-2091&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1460-2091&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1460-2091&client=summon